A bone-based 3D scaffold as an
3D
diffuse B-cell lymphoma
extracellular matrix
mesenchymal stroma cell
organoid
scaffold
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
19
05
2022
accepted:
22
09
2022
entrez:
4
11
2022
pubmed:
5
11
2022
medline:
5
11
2022
Statut:
epublish
Résumé
About 30% of patients with diffuse large B-cell lymphoma (DLBCL) relapse or exhibit refractory disease (r/r DLBCL) after first-line immunochemotherapy. Bone marrow (BM) involvement confers a dismal prognosis at diagnosis, likely due to the interaction between neoplastic cells and a complex tumor microenvironment (TME). Therefore, we developed a 3D
Identifiants
pubmed: 36330473
doi: 10.3389/fonc.2022.947823
pmc: PMC9623125
doi:
Types de publication
Journal Article
Langues
eng
Pagination
947823Informations de copyright
Copyright © 2022 Ceccato, Piazza, Pizzi, Manni, Piazza, Caputo, Cinetto, Pisoni, Trojan, Scarpa, Zambello, Tos, Trentin, Semenzato and Vianello.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Leukemia. 1999 Sep;13(9):1428-33
pubmed: 10482995
Blood. 2000 Mar 15;95(6):1900-10
pubmed: 10706853
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Biomaterials. 2016 Jan;74:31-41
pubmed: 26433490
Haematologica. 2010 Jul;95(7):1081-9
pubmed: 20179085
Lab Invest. 2014 Nov;94(11):1212-23
pubmed: 25199050
Trends Cancer. 2021 Mar;7(3):249-264
pubmed: 33218948
Front Immunol. 2021 Dec 08;12:784691
pubmed: 34956214
Stem Cells. 2011 Oct;29(10):1549-58
pubmed: 21898680
Nat Rev Mater. 2018 May;3(5):21-37
pubmed: 31223488
ACS Biomater Sci Eng. 2016 Oct 10;2(10):1710-1721
pubmed: 28251176
Mater Sci Eng C Mater Biol Appl. 2019 Dec;105:110039
pubmed: 31546422
EMBO Rep. 2014 Dec;15(12):1243-53
pubmed: 25381661
Haematologica. 2018 Jan;103(1):116-125
pubmed: 29079592
Front Mol Biosci. 2020 Jan 31;6:160
pubmed: 32118030
J Clin Pathol. 2003 Oct;56(10):747-52
pubmed: 14514777
Front Bioeng Biotechnol. 2021 Apr 12;9:660502
pubmed: 33912551
N Engl J Med. 2018 Apr 12;378(15):1396-1407
pubmed: 29641966
Leukemia. 2018 Feb;32(2):353-363
pubmed: 28745330
EBioMedicine. 2020 Nov;61:103055
pubmed: 33096480
J Cell Sci. 1995 Apr;108 ( Pt 4):1723-33
pubmed: 7542258
Front Immunol. 2021 Feb 08;11:605231
pubmed: 33628205
Cancers (Basel). 2021 Aug 12;13(16):
pubmed: 34439218
J Exp Clin Cancer Res. 2019 Feb 12;38(1):73
pubmed: 30755239
Biomaterials. 2014 Mar;35(8):2454-61
pubmed: 24388382
Neoplasia. 2015 Jan;17(1):1-15
pubmed: 25622895
J Pathol. 2020 Apr;250(5):555-572
pubmed: 31608444
Nat Cell Biol. 2013 Jul;15(7):807-17
pubmed: 23728425
Ann Hematol. 2015 May;94(5):803-12
pubmed: 25501975